Jianghong Fan

机构：United States Food and Drug Administration, Center for Drug Evaluation and Research · ORCID：0000-0001-5996-6385

发表论文 62 篇 · 总被引 2540 次 · h-index 26

代表论文

• Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018‐2019 Submissions to the US FDA's Office of Clinical Pharmacology (2020 · The Journal of Clinical Pharmacology · 被引 181)
• FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer (2020 · Clinical Cancer Research · 被引 171)
• FDA Approval Summary: Selumetinib for Plexiform Neurofibroma (2021 · Clinical Cancer Research · 被引 108)
• Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019 (2020 · Clinical Infectious Diseases · 被引 77)
• FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer (2020 · Clinical Cancer Research · 被引 63)
• US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer (2024 · Journal of Clinical Oncology · 被引 44)